key: cord-0905045-autjh614
authors: Inoue, Sumito; Igarashi, Akira; Morikane, Keita; Hachiya, Osamu; Watanabe, Masafumi; Kakehata, Seiji; Sato, Shinya; Ueno, Yoshiyuki
title: Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
date: 2021-12-07
journal: Respir Investig
DOI: 10.1016/j.resinv.2021.11.007
sha: 44a9f3b3dd3ff7e1814cc932d72f3df5ef9773f3
doc_id: 905045
cord_uid: autjh614

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) vaccination is progressing globally. Several adverse reactions have been reported with vaccination against COVID-19. It is unknown whether adverse reactions to COVID-19 vaccination are severe in individuals with allergies. METHODS: We administered the COVID-19 vaccine to the medical staff at Yamagata University Hospital from March to August 2021. Subsequently, we conducted an online questionnaire-based survey to investigate the presence of allergy and adverse reactions after vaccination and examine the association between allergy and adverse reactions after immunization. RESULTS: Responses were collected from 1586 and 1306 participants after the first and second administration of the BNT162b2 mRNA COVID-19 vaccine, respectively. Adverse reactions included injection site pain, injection site swelling, fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the injection site, and arthralgia. The frequency of some adverse reactions and their severity were higher, and the duration of symptoms was longer in participants with allergies than in those without allergies. Although several participants visited the emergency room for treatment after the first and second vaccinations, no participant was diagnosed with anaphylaxis. CONCLUSIONS: This study suggests that the frequency and severity of adverse reactions after injection of BNT162b2 mRNA COVID-19 vaccine were higher in individuals with allergy; however, no severe adverse reactions such as anaphylaxis or death were observed. These results indicate that individuals with allergic histories may tolerate the BNT162b2 mRNA COVID-19 vaccine.

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-68 19) pandemic continues to spread worldwide, COVID-19 vaccination is one of the 69 solutions to control it. BNT162b2 mRNA COVID-19 vaccine (Pfizer Inc. NY, USA, 70

BioNTech SE, Mainz, Germany) was the first available mRNA vaccine in Japan 71 since February 2021, and was initially administered to healthcare workers [1] . 72

Currently, several types of COVID-19 vaccines are available, and many people 73 are being vaccinated [1] [2] [3] . Although the efficacy of COVID-19 vaccination varies 74 depending on the type of vaccine, the BNT162b2 has been reported to be 95% 75 effective in preventing symptomatic COVID-19 infection in vaccinated individuals, 76 indicating its high efficacy [1] . Effective medications against COVID-19 include 77 dexamethasone [4, 5] , antiviral agent remdesivir [6] , and Janus kinase (JAK) 78 inhibitor baricitinib [7] , all of which are currently available in Japan for COVID-19 79 treatment. Although various other drugs are therapeutic options for COVID-19 80 treatment, reports have described their inefficacy, including for those currently 81 available; hence, no reliable treatment is available [8] . 82 Therefore, suppression of the COVID-19 pandemic by vaccination is considered 83 6 such as allergy or severe anaphylaxis. Particularly, it is difficult to determine 91 whether individuals with allergies can receive the COVID-19 vaccine. However, 92

to verify the safety of COVID-19 vaccines, individuals with a history of allergy to 93 vaccine components were excluded from clinical trials. As a result, very few 94 studies have examined the safety of COVID-19 vaccination in people with 95 allergies. 96

At Yamagata University Hospital, in Japan, BNT162b2 was administered to 97 hospital staff and students. After vaccination, we conducted a questionnaire 98 survey to investigate their allergic history and adverse reactions after 99 immunization. By analyzing these data, we aimed to verify the safety of the 100 COVID-19 vaccine in people with a history of allergy. 101 J o u r n a l P r e -p r o o f There were 1586 questionnaires returned from individuals who had received the 132 first vaccination of BNT162b2, and 1306 questionnaires from individuals who had 133 received the second vaccination after approximately 3 weeks. Table 1 The profiles were similar to those after the second vaccination. The frequencies 143 of allergic histories by gender and age are summarized in Table 2. In the first and  144 second vaccinations, the frequencies of history of allergies to food and/or 145 medicine, and history of adverse reactions after vaccination were significantly 146 higher in female than in male individuals. In the first vaccination, the frequency of 147 history of allergies to food and/or medicine was significantly higher in older than 148 in younger individuals. In the second vaccination, the frequency of history of 149 anaphylaxis was significantly higher in older than in younger individuals. 150

The frequency of adverse reactions after the first and second vaccinations is 151 shown in Figure 1 . Adverse reactions other than pain at the injection site occurred 152 more frequently after the second vaccination. 153 Table 3 summarizes the frequency of adverse reactions by gender and age. The 154 J o u r n a l P r e -p r o o f frequency of fatigue or malaise, headache, chills, nausea, and muscle pain 155 outside the injection site after the first vaccination was significantly higher in 156 female than in male individuals. After the second vaccination, the frequency of 157 fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the 158 injection site, and arthralgia was significantly higher in female than in male 159 individuals. No adverse reactions had a significantly higher incidence in male 160 individuals. In the analysis by age, the frequency of injection site pain, injection 161 site swelling, fever, and nausea after the first vaccination was significantly higher 162 in younger people. The frequency of injection site pain, fever, fatigue or malaise, 163 headache, chills, nausea, and muscle pain outside the injection site after the 164 second vaccination was significantly higher in the younger age group. 165 Table 4 summarizes the frequency of adverse reactions by allergic status. Those 166 who had a history of allergy to food and/or medicine had a significantly higher 167 incidence of fatigue or malaise, headache, chills, nausea, and arthralgia after the 168 first vaccination and a higher incidence of headache, nausea, muscle pain 169 outside the injection site, and arthralgia after the second vaccination than those 170 without a history of allergy to food and/or medicine. Those who had a history of 171 allergic diseases, such as bronchial asthma and allergic rhinitis, had a 172 significantly higher incidence of injection site pain, injection site swelling, fever, 173 fatigue or malaise, headache, nausea, and arthralgia after the first vaccination, 174 and a higher incidence of injection site swelling and nausea after the second 175 vaccination than those without a history of allergic diseases. Those who had a 176 history of anaphylaxis had a significantly higher incidence of fatigue or malaise 177 after the first vaccination and a lower incidence of headache after the second vaccination than those without a history of anaphylaxis. Those who had a history 179 of adverse reactions after vaccination had a significantly higher incidence of 180 injection site swelling, fever, fatigue or malaise, headache, and chills after the first 181 vaccination and a higher incidence of injection site pain and injection site swelling, 182 nausea, and arthralgia after the second vaccination than those without a history 183 of adverse reactions after vaccination. 184 Table 5 shows whether individuals with allergies continued to have adverse 185 reactions after vaccination for a long period. The frequency of fatigue or malaise 186 after the first and second vaccinations and headache and chills after the second 187 vaccination, lasting more than 2 days, was significantly higher among participants 188 with a history of allergy to food and/or medicine than in those without. The 189 frequency of fever after the first vaccination and injection site pain after the 190 second vaccination, lasting more than 2 days, was significantly higher among 191 participants with a history of allergy than in those without. The frequency of 192 adverse reactions lasting more than 2 days after vaccination did not differ with 193 the presence or absence of a history of anaphylaxis. The frequency of fatigue or 194 malaise and headache after the second vaccination, lasting more than 2 days, 195 was significantly higher among participants with a history of adverse reactions 196 after vaccination than in those without. 197 Table 6 demonstrates whether the frequency of moderate to severe adverse 198 reactions after vaccination differs, according to the presence or absence of allergy. 199

Individuals with a history of allergy to food and/or medicine had a significantly likely to have a history of allergy; however, they may have been exposed to more 223 foods and medications that could cause allergies during their long lifetime. In this 224 study, after the vaccination of BNT162b2, the rate of adverse reactions was 225 higher in female and younger individuals than in male and older individuals, 226 respectively. These results were consistent with previous reports [13] . 227

Participants who had a history of allergy to food and/or medicine, allergic 228 diseases such as bronchial asthma or allergic rhinitis, a history of anaphylaxis, or 229 adverse reactions after vaccination had a significantly higher frequency of some 230 adverse reactions compared to those without. Some adverse reactions showed 231 a higher frequency of longer symptom duration after vaccination and a higher 232 frequency of moderate or severe adverse reactions, but the differences were not 233 remarkably large. Additionally, no severe life-threatening allergic events were 234 experienced after the BNT162b2 vaccination at our hospital. 235

In a previous report, the COVID-19 vaccination of hospital staff was performed, 236 or absence of allergy [14] . They found that participants with a history of allergy 238 had a significantly higher incidence of adverse reactions after vaccination than 239 those without. They concluded that the BNT162b2 is less tolerated in individuals 240 with allergy than in those without allergy, but the adverse reactions that occurred 241 were mild and did not interfere with the successful completion of vaccination. Our 242 results and conclusions are comparable, although our study is valuable since we 243 did not only investigate the presence or absence of allergy but also a detailed 244 history of anaphylaxis and previous histories of adverse reactions to vaccination. 245 Furthermore, our data are from the Japanese population. Therefore, we believe 246 that our findings will be useful information for Japanese people who have a history 247 of allergy to food and/or medicine, history of allergic diseases, history of 248 anaphylaxis, and history of adverse reactions to vaccination. 249

There were several limitations to our study. First, the survey was an internet-250 based questionnaire, and symptoms and allergy history were self-reported. 251

Particularly, it is unclear whether the diagnosis of allergic diseases was correct. 252 Second, few participants had a history of anaphylaxis or adverse reactions to 253 vaccinations; thus, the statistical reliability of the study may not be high. 254

Anaphylaxis was reported at a rate of 11.1 per million doses of BNT162b2 255 vaccination [15] . We need to consider that with the number of individuals who 256 participated in this study, we may not be able to detect severe adverse reactions 257 such as anaphylaxis or death. Third, it is possible that some of the staff did not 

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic 354 Reactions: Current Evidence and Suggested Approach